This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30. doi: 10.3322/caac.21590SiegelRLMillerKDJemalACancer statistics, 2010CA Cancer J Clin20207073010.3322/caac.21590Open DOISearch in Google Scholar
Bryan DS, Donington JS. The role of surgery in management of locally advanced non-small cell lung cancer. Curr Treat Option Oncol 2019; 20: 27. doi: 10.1007/s11864-019-0624-7BryanDSDoningtonJSThe role of surgery in management of locally advanced non-small cell lung cancerCurr Treat Option Oncol2019202710.1007/s11864-019-0624-7Open DOISearch in Google Scholar
Jeremic B. Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy. Clin Lung Cancer 2015; 16: 80-5. doi: 10.1016/j.cllc.2014.08.003JeremicBStandard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapyClin Lung Cancer20151680510.1016/j.cllc.2014.08.003Open DOISearch in Google Scholar
Burdett S, Parmar MKB, Steward LA, Souhami RL, Arriagada R, Girling DJ, et al; PORT Meta-analysis Trialists Group. Post-operative radiotherapy in non-small cell lung cancer: a systematic meta-analysis using individual data from nine randomised controlled trials. Lancet 1998; 352: 257-63.BurdettSParmarMKBStewardLASouhamiRLArriagadaRGirlingDJet alPORT Meta-analysis Trialists Group. Post-operative radiotherapy in non-small cell lung cancer: a systematic meta-analysis using individual data from nine randomised controlled trialsLancet19983522576310.1016/S0140-6736(98)06341-7Search in Google Scholar
Sakib N, Li N, Zhu X, Li D, Li Y, Wang H. Effect of postoperative radiotherapy on outcome in resectable stage IIIA-N2 non-small-cell lung cancer: an updated meta-analysis. Nucl Med Commun 2018; 39: 51-59. doi: 10.1097/MNM.0000000000000764SakibNLiNZhuXLiDLiYWangHEffect of postoperative radiotherapy on outcome in resectable stage IIIA-N2 non-small-cell lung cancer: an updated meta-analysisNucl Med Commun201839515910.1097/MNM.000000000000076429189442Open DOISearch in Google Scholar
Le Pechoux C, Pourel N, Barlesi F, Faivre-Finn C, Lerouge D, Zalcman G, et al. LBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683. [Abstract]. Ann Oncol 2020; 31(Suppl 4): S1178-S1178.Le PechouxCPourelNBarlesiFFaivre-FinnCLerougeDZalcmanGet alLBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683. [Abstract]Ann Oncol202031Suppl 4S1178S117810.1016/j.annonc.2020.08.2280Search in Google Scholar
Matsuguma H, Nakahara R, Ishikawa Y, Suzuki H, Inoue K, Katano S, et al. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involved Interact Cardiovasc Thorac Surg 2008; 7: 573-7. doi: 10.1510/icvts.2007.174342MatsugumaHNakaharaRIshikawaYSuzukiHInoueKKatanoSet alPostoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involvedInteract Cardiovasc Thorac Surg20087573710.1510/icvts.2007.17434218413349Open DOISearch in Google Scholar
Wang S, Ma Z, Yang X, Wang Y, Xu Y, Xia W, et al. Choice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node number. Radiat Oncol 2017; 12: 207. doi: 10.1186/s13014-017-0946-1WangSMaZYangXWangYXuYXiaWet alChoice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node numberRadiat Oncol20171220710.1186/s13014-017-0946-1574717229284511Open DOISearch in Google Scholar
Shang X, Li Z, Lin J, Wang H, Wang Z. PLNR</=20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study. Cancer Manag Res 2018; 10: 3561-7. doi: 10.2147/CMAR.S173856ShangXLiZLinJWangHWangZPLNR</=20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based studyCancer Manag Res2018103561710.2147/CMAR.S173856615260230271204Open DOISearch in Google Scholar
Nguyen SK, Masson-Cote L, Fortin A, Dagnault A. Influence of smoking status on treatment outcomes after post-operative radiation therapy for non-small-cell lung cancer. Radiother Oncol 2010; 96: 89-93. doi: 10.1016/j. radonc.2010.05.008NguyenSKMasson-CoteLFortinADagnaultAInfluence of smoking status on treatment outcomes after post-operative radiation therapy for non-small-cell lung cancerRadiother Oncol201096899310.1016/j.radonc.2010.05.00820541274Open DOISearch in Google Scholar
Yoshino I, Yoshida S, Miyaoka E, Asamura H, Nomori H, Fujii Y, et al. Surgical outcome of stage IIIA-cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004. J Thorac Oncol 2012; 7: 850-5. doi: 10.1097/JTO.0b013e31824c945bYoshinoIYoshidaSMiyaokaEAsamuraHNomoriHFujiiYet alSurgical outcome of stage IIIA-cN2/pN2 non-small-cell lung cancer patients in Japanese lung cancer registry study in 2004J Thorac Oncol20127850510.1097/JTO.0b013e31824c945b22481238Open DOISearch in Google Scholar
Kou P, Wang H, Lin J, Zhang Y, Yu J. Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis. Future Oncol 2018; 14: 2371-81. doi: 10.2217/fon-2018-0326KouPWangHLinJZhangYYuJMale patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysisFuture Oncol20181423718110.2217/fon-2018-032629807451Open DOISearch in Google Scholar
Kumar V, Robbins SL, Abbas AK, Aster JC. Robbins basic pathology. 9th edition. Philadelphia, PA: Elsevier/Saunders; 2013.KumarVRobbinsSLAbbasAKAsterJCRobbins basic pathology9th editionPhiladelphia, PAElsevier/Saunders2013Search in Google Scholar
Pasche B, Grant SC. Non-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial design. JAMA 2014; 311: 1975-6. doi: 10.1001/jama.2014.3742PascheBGrantSCNon-small cell lung cancer and precision medicine: a model for the incorporation of genomic features into clinical trial designJAMA20143111975610.1001/jama.2014.374224846033Open DOISearch in Google Scholar
Perez-Moreno P, Brambilla E, Thomas R, Soria JC. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities. Clin Cancer Res 2012; 18: 2443-51. doi: 10.1158/1078-0432.CCR-11-2370.Perez-MorenoPBrambillaEThomasRSoriaJCSquamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunitiesClin Cancer Res20121824435110.1158/1078-0432.CCR-11-237022407829Open DOISearch in Google Scholar
Varlotto JM, Recht A, Flickinger JC, Medford-Davis LN, Dyer AM, Decamp MM. Factors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancer. Cancer 2009; 115: 1059-69. doi: 10.1002/cncr.24133VarlottoJMRechtAFlickingerJCMedford-DavisLNDyerAMDecampMMFactors associated with local and distant recurrence and survival in patients with resected non-small cell lung cancerCancer200911510596910.1002/cncr.2413319152440Open DOISearch in Google Scholar
Dai H, Hui Z, Ji W, Liang J, Lu J, Ou G, et al. Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. Oncologist 2011; 16: 641-50. doi: 10.1634/theoncologist.2010-0343DaiHHuiZJiWLiangJLuJOuGet alPostoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institutionOncologist2011166415010.1634/theoncologist.2010-0343322820021482587Open DOISearch in Google Scholar
Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest 2017; 151: 193-203. doi: 10.1016/j. chest.2016.10.010DetterbeckFCBoffaDJKimAWTanoueLTThe eighth edition lung cancer stage classificationChest201715119320310.1016/j.chest.2016.10.01027780786Open DOISearch in Google Scholar
Robinson CG, Patel AP, Bradley JD, DeWees T, Waqar SN, Morgenszternet D, et al. Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base. J Clin Oncol 2015; 33: 870-6. doi: 10.1200/JCO.2014.58.5380RobinsonCGPatelAPBradleyJDDeWeesTWaqarSNMorgenszternetDet alPostoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data BaseJ Clin Oncol201533870610.1200/JCO.2014.58.5380434863525667283Open DOISearch in Google Scholar
Zou B, Xu Y, Li T, Li W, Tang B, Zhou L, et al. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal disease. Int J Radiat Oncol Biol Phys 2010; 77: 321-8. doi: 10.1016/j.ijrobp.2009.05.044ZouBXuYLiTLiWTangBZhouLet alA multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with N2 nodal diseaseInt J Radiat Oncol Biol Phys201077321810.1016/j.ijrobp.2009.05.04419775829Open DOISearch in Google Scholar
Liu T, Mu Y, Dang J, Li G. The role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysis. J Cancer 2019; 10: 3941-9. doi: 10.7150/jca.28680LiuTMuYDangJLiGThe role of postoperative radiotherapy for completely resected pIIIA-N2 non-small cell lung cancer patients with different clinicopathological features: a systemic review and meta-analysisJ Cancer2019103941910.7150/jca.28680669261631417638Open DOISearch in Google Scholar
Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer 2014; 14: 535-46. doi: 10.1038/nrc3775ChenZFillmoreCMHammermanPSKimCFWongKNon-small-cell lung cancers: a heterogeneous set of diseasesNat Rev Cancer2014145354610.1038/nrc3775Open DOISearch in Google Scholar
Davidson MR, Gazdar AF, Clarke BE. The pivotal role of pathology in the management of lung cancer. J Thorac Dis 2013; 5(Suppl 5): S463-78. doi: 10.3978/j.issn.2072-1439.2013.08.43DavidsonMRGazdarAFClarkeBEThe pivotal role of pathology in the management of lung cancerJ Thorac Dis20135Suppl 5S4637810.3978/j.issn.2072-1439.2013.08.43Open DOISearch in Google Scholar
Moretti L, Yu DS, Chen H, David P, Carbone DP, Johnson DH, Keedy VL, et al. Prognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapy. Oncologist 2009; 14: 1106-15. doi: 10.1634/theoncologist.2009-0130MorettiLYuDSChenHDavidPCarboneDPJohnsonDHKeedyVLet alPrognostic factors for resected non-small cell lung cancer with pN2 status: implications for use of postoperative radiotherapyOncologist20091411061510.1634/theoncologist.2009-0130Open DOISearch in Google Scholar
Koutsoukos K, Mountzios G. Novel therapies for advanced squamous cell carcinoma of the lung. Future Oncol 2016; 12: 659-67. doi: 10.2217/fon.15.358KoutsoukosKMountziosGNovel therapies for advanced squamous cell carcinoma of the lungFuture Oncol2016126596710.2217/fon.15.358Open DOISearch in Google Scholar
Feng QF, Wang M, Wang LJ, Yang ZY, Zhang YG, Zhang DW, et al. A study of postoperative radiotherapy in patients with non–small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2000; 47: 925-9. doi: 10.1016/S0360-3016(00)00509-5FengQFWangMWangLJYangZYZhangYGZhangDWet alA study of postoperative radiotherapy in patients with non–small-cell lung cancer: a randomized trialInt J Radiat Oncol Biol Phys200047925910.1016/S0360-3016(00)00509-5Open DOISearch in Google Scholar
Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315: 1377-81. doi: 10.1056/NEJM198611273152202Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lungN Engl J Med198631513778110.1056/NEJM198611273152202Open DOISearch in Google Scholar
Hui Z, Dai H, Liang J, Lv J, Zhou Z, Feng Q, et al. Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy. Thorac Cancer 2015; 6: 346-53. doi: 10.1111/1759-7714.12186HuiZDaiHLiangJLvJZhouZFengQet alSelection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapyThorac Cancer201563465310.1111/1759-7714.12186Open DOISearch in Google Scholar
Consonni D, Pierobon M, Gail MH, Rubagotti M, Rotunno M, Goldsteinet A, et al. Lung cancer prognosis before and after recurrence in a population-based setting. J Natl Cancer Inst 2015; 107: v59. doi: 10.1093/jnci/djv059ConsonniDPierobonMGailMHRubagottiMRotunnoMGoldsteinetAet alLung cancer prognosis before and after recurrence in a population-based settingJ Natl Cancer Inst2015107v5910.1093/jnci/djv059Open DOISearch in Google Scholar
Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-27. doi: 10.1016/S1470-2045(06)70804-XDouillardJYRosellRDe LenaMCarpagnanoFRamlauRGonzáles-LarribaJLet alAdjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialLancet Oncol200677192710.1016/S1470-2045(06)70804-XOpen DOISearch in Google Scholar
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-39. doi: 10.1056/NEJMoa040938LynchTJBellDWSordellaRGurubhagavatulaSOkimotoRABranniganBWet alActivating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinibN Engl J Med200435021293910.1056/NEJMoa04093815118073Open DOISearch in Google Scholar
Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-34. doi: 10.1200/JCO.2012.44.2806SequistLVYangJCYamamotoNO’ByrneKHirshVMokTet alPhase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutationsJ Clin Oncol20133133273410.1200/JCO.2012.44.2806Open DOISearch in Google Scholar
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735-42. doi: 10.1016/S1470-2045(11)70184-XZhouCWuYLChenGFengJLiuXQWangCet alErlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyLancet Oncol2011127354210.1016/S1470-2045(11)70184-XOpen DOISearch in Google Scholar
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380-8. doi: 10.1056/NEJMoa0909530MaemondoMInoueAKobayashiKSugawaraSOizumiSIsobeHet alGefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFRN Engl J Med20103622380810.1056/NEJMoa0909530Open DOISearch in Google Scholar
Zhong W, Wang Q, Mao W, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19: 139-48. doi: 10.1016/S1470-2045(17)30729-5ZhongWWangQMaoWXuSTWuLShenYet alGefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 studyLancet Oncol2018191394810.1016/S1470-2045(17)30729-5Open DOISearch in Google Scholar
Tang W, Li X, Xie X, Sun X, Liu J, Zhang J, et al. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations. Lung Cancer 2019; 136: 6-14. doi: 10.1016/j.lungcan.2019.08.001TangWLiXXieXSunXLiuJZhangJet alEGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutationsLung Cancer201913661410.1016/j.lungcan.2019.08.001Open DOISearch in Google Scholar
Khuder SA. Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis. Lung Cancer 2001; 31: 139-48. doi: 10.1016/s0169-5002(00)00181-1KhuderSAEffect of cigarette smoking on major histological types of lung cancer: a meta-analysisLung Cancer2001311394810.1016/s0169-5002(00)00181-1Open DOISearch in Google Scholar
Yeh SJ, Chang CA, Li CW, Wang LH, Chen BS. Comparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identification. Oncotarget 2019; 10: 3760-806. doi: 10.18632/oncotarget.26940YehSJChangCALiCWWangLHChenBSComparing progression molecular mechanisms between lung adenocarcinoma and lung squamous cell carcinoma based on genetic and epigenetic networks: big data mining and genome-wide systems identificationOncotarget201910376080610.18632/oncotarget.26940655719931217907Open DOISearch in Google Scholar
Li N, Zhao J, Ma Y, Roy B, Liu R, Kristiansen K, et al. Dissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinoma. Oncol Lett 2018; 16: 3992-4000. doi: 10.3892/ol.2018.9113LiNZhaoJMaYRoyBLiuRKristiansenKet alDissecting the expression landscape of mitochondrial genes in lung squamous cell carcinoma and lung adenocarcinomaOncol Lett2018163992400010.3892/ol.2018.9113609609930128019Open DOISearch in Google Scholar
Lin YK, Hsu HL, Lin WC, Chang JH, Chang YC, Chang CL, et al. Efficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancer. Oncotarget 2017; 8: 35280-8. doi: 10.18632/onco-target.13257LinYKHsuHLLinWCChangJHChangYCChangCLet alEfficacy of postoperative radiotherapy in patients with pathological stage N2 epidermal growth factor receptor wild type adenocarcinoma and squamous cell carcinoma lung cancerOncotarget2017835280810.18632/onco-target.13257Open DOISearch in Google Scholar
